Yuan Hao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuan Hao has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Charles M. Rudin
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
20 shared publications - Kwok-Kin Wong
Division of Hematology & Medical Oncology, NYU Langone Perlmutter Cancer Center, New York, USA
20 shared publications - Michael Cross
Laboratory of Skin Biology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA
19 shared publications - Ray Pillai
Department of Pathology, New York University Grossman School of Medicine, New York, NY, USA
19 shared publications - Sahith Rajalingam
Department of Pathology, New York University Grossman School of Medicine
19 shared publications - Thales Papagiannakopoulos
Department of Pathology, New York University Grossman School of Medicine, New York, USA
19 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF21
ACKR3 Establishes a Squamous-Restricted Immune Checkpoint Axis in Lung Squamous Cell Carcinoma
Lung squamous cell carcinoma (LUSC) is an aggressive subtype of non–small cell lung cancer (NSCLC) with limited targeted therapeutic options and incompletely defined immunoregulatory dependencies. In this study, we identified atypical chemokine receptor 3 (ACKR3) as a squamous-enriched regulator that restrains malignant progression in LUSC. Integrative analyses of human LUSC datasets, autochthonous genetically engineered mouse models (GEMM), and ex vivo organoid systems showed that ACKR3 loss accelerated tumor growth and remodeled the immune microenvironment, marked by reduced CD8+ T-cell infiltration and increased T-cell exhaustion. Mechanistically, ACKR3 limited the activation of the macrophage migration inhibitory factor (MIF)–CD74–PD-L1 axis, thereby constraining tumor-cell PD-L1 expression and preserving antitumor immune surveillance. In preclinical LUSC models, treatment with the ACKR3-directed PD-L1 degrader, cytokine receptor–targeting chimera (KineTAC), a bispecific molecule that coengages ACKR3 and PD-L1 to promote lysosomal degradation of PD-L1, enhanced antitumor efficacy, particularly in combination with chemotherapy. Together, these findings define ACKR3 as a squamous-associated immune checkpoint regulator and nominate ACKR3-directed PD-L1 degradation as a tumor-selective therapeutic strategy for LUSC. Significance: ACKR3 is a lineage-imprinted checkpoint restraining MIF–CD74–driven PD-L1 induction in lung squamous cell carcinoma that can be harnessed for PD-L1 degradation to induce tumor-restricted checkpoint dismantling.
- 9 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF21
Open AccessACKR3 Establishes a Squamous-Restricted Immune Checkpoint Axis in Lung Squamous Cell Carcinoma
Lung squamous cell carcinoma (LUSC) is an aggressive subtype of non–small cell lung cancer (NSCLC) with limited targeted therapeutic options and incompletely defined immunoregulatory dependencies. In this study, we identified atypical chemokine receptor 3 (ACKR3) as a squamous-enriched regulator that restrains malignant progression in LUSC. Integrative analyses of human LUSC datasets, autochthonous genetically engineered mouse models (GEMM), and ex vivo organoid systems showed that ACKR3 loss accelerated tumor growth and remodeled the immune microenvironment, marked by reduced CD8+ T-cell infiltration and increased T-cell exhaustion. Mechanistically, ACKR3 limited the activation of the macrophage migration inhibitory factor (MIF)–CD74–PD-L1 axis, thereby constraining tumor-cell PD-L1 expression and preserving antitumor immune surveillance. In preclinical LUSC models, treatment with the ACKR3-directed PD-L1 degrader, cytokine receptor–targeting chimera (KineTAC), a bispecific molecule that coengages ACKR3 and PD-L1 to promote lysosomal degradation of PD-L1, enhanced antitumor efficacy, particularly in combination with chemotherapy. Together, these findings define ACKR3 as a squamous-associated immune checkpoint regulator and nominate ACKR3-directed PD-L1 degradation as a tumor-selective therapeutic strategy for LUSC. Significance: ACKR3 is a lineage-imprinted checkpoint restraining MIF–CD74–driven PD-L1 induction in lung squamous cell carcinoma that can be harnessed for PD-L1 degradation to induce tumor-restricted checkpoint dismantling.
- Top Cited Papers
- 2 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 393 (6806) , 90-97
A dietary switch promotes sensory neuron–dependent cancer-associated cachexia
Sickness behaviors are common in cancer-associated cachexia and affect up to half of lung cancer patients. We demonstrate that among the most common cancer mutations, loss of liver kinase B1 ( Lkb1 ) promotes the development of cachexia in preclinical models of lung cancer. In an effort to improve caloric intake with an obesogenic high-fat diet, we paradoxically observed worsened cachexia-associated sickness. We found that local production of prostaglandin E2 (PGE 2 ), rather than circulating factors, promotes sickness and that genetic, dietary, and pharmacological inhibition of tumor-derived PGE 2 suppresses sickness and cachexia. Notably, we demonstrate that lung sensory neuron abrogation prevents PGE 2 -dependent cachexia. Our study establishes localized tumor-derived signals to sensory neurons, rather than circulating factors, as drivers of cachexia and highlights a previously unknown role of the peripheral nervous system in cancer cachexia.
- 2 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 393 (6806) , 90-97
Top Cited PapersA dietary switch promotes sensory neuron–dependent cancer-associated cachexia
Sickness behaviors are common in cancer-associated cachexia and affect up to half of lung cancer patients. We demonstrate that among the most common cancer mutations, loss of liver kinase B1 ( Lkb1 ) promotes the development of cachexia in preclinical models of lung cancer. In an effort to improve caloric intake with an obesogenic high-fat diet, we paradoxically observed worsened cachexia-associated sickness. We found that local production of prostaglandin E2 (PGE 2 ), rather than circulating factors, promotes sickness and that genetic, dietary, and pharmacological inhibition of tumor-derived PGE 2 suppresses sickness and cachexia. Notably, we demonstrate that lung sensory neuron abrogation prevents PGE 2 -dependent cachexia. Our study establishes localized tumor-derived signals to sensory neurons, rather than circulating factors, as drivers of cachexia and highlights a previously unknown role of the peripheral nervous system in cancer cachexia.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
Gating strategy for immune cells.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
Gating strategy for immune cells.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S2 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
Immune Analysis of Lkb1 mutant lung tumors by scRNA-seq.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S2 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
Immune Analysis of Lkb1 mutant lung tumors by scRNA-seq.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
Immune analysis of murine Lkb1 mutant lung tumors by flow cytometry.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
Immune analysis of murine Lkb1 mutant lung tumors by flow cytometry.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
Loss of function mutations in Lkb1 enhance tumorigenesis.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
Loss of function mutations in Lkb1 enhance tumorigenesis.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
Depletion of interstitial macrophages in Lkb1 mutant lung tumors after clodronate administration increases effector T cell function.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
Depletion of interstitial macrophages in Lkb1 mutant lung tumors after clodronate administration increases effector T cell function.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S13 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
LIF neutralization eliminates a dedifferentiated stem-like tumor cell state.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S13 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
LIF neutralization eliminates a dedifferentiated stem-like tumor cell state.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
Lkb1 mutant tumors transcriptionally upregulate the cytokine LIF.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
Lkb1 mutant tumors transcriptionally upregulate the cytokine LIF.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
Autocrine LIF signaling enhances tumorigenesis and inflammation.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
Autocrine LIF signaling enhances tumorigenesis and inflammation.